-
The first antibody drug to target BCMA, Blenrep, was approved by the FDA for accelerated treatment of recurrent or recurrent multiple myeloma.
Time of Update: 2020-08-22
GlaxoSmithKline announced that the FDA has accelerated approval of Belantamab mafodotin-blmf for the treatment of adult patients with recurrent or recurrent multiple myeloma who have received at least four previous treatments, including anti-CD38 monoclonal antibodies, protease inhibitors, and immunomodants.
-
Blood: The efficacy of BTKi, a self-developed drug, in the long-term treatment of Fahrenheit globulinemia.
Time of Update: 2020-08-22
ORR and VGPR/CR rates were 95.9 per cent and 45.2 per cent, respectively, and the VGPR/CR rates increased over time: 20.5 per cent at 6 months, 32.9 per cent at 12 months and 43.8 per cent at 24 months.
-
CELL: Congenital immunomarkers distinguish new coronary high-risk patients.
Time of Update: 2020-08-22
13 SARS-CoV-2-positive patients ('COVID-19 patients') and 12 non-new crown patients with flu-like symptoms were detected by RT-PCR.
-
Blood:Phase 3 trial: Two sets of BTK inhibitors to treat Fahrenheit globulinemia!
Time of Update: 2020-08-22
29 (28%) and 19 (19%) patients in the zanubrutinib and Irutinib groups received VGPR, respectively, but the differences between the two groups were not statistically significant (P-0.09); did not reach the mid-level DOR and PFS, and the 18-month non-progress survival rates of the Irutini and Zanubrutinib groups were 84% and 85%, respectively.
-
Blood: Tissue factor pathway inhibitors are involved in cerebrovascular development.
Time of Update: 2020-08-22
researchers observed that other systemic tissues in the Tfpi-/-embryo developed normally except for the central nervous system.
removal of FV from Tfpi-/- embryos can completely improve their brain lesions, suggesting that TFPI inhibits the clotting activity of FV dependence in a way that regulates cerebrovascular development.
-
GSK's anti-BCMA drug for multiple myeloma has been approved and is back in the anti-tumor field.
Time of Update: 2020-08-22
see: Key research on the anti-BCMA drug belantamab mafodotin for multiple myeloma reaches its main end point, but eye toxicity is also of concern: antibody-drug concatenation Belanamab mafodotin: Alarming eye toxicity At the end of May this year, GSK published the study's 13-month follow-up data at the 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO).
-
Brit J Heamatol: Characteristics and prognosis of patients with cytoblast reduction disorders associated with cytoma virus.
Time of Update: 2020-08-22
at all hematology centers in Israel, researchers searched adult patients with normal immune function with CMV-related plateboard reduction and found five new cases.
, these unique characteristics of patients with plate plateroid reduction alert medical staff that CMV infection may be the cause.
-
NEJM: Suspended Amyloid Degeneration - Case Report.
Time of Update: 2020-08-22
amyloid degenerative disease is characterized by abnormal protein deposition in extracellular tissue.
light-chain form of disease, extracellular tissue originates from the immunoglobulin light chain associated with plasma cells.
-
Clin Cancer Res: Follow up for 8 years! Irutini treatment CLL/SLL long-term effective!
Time of Update: 2020-08-22
PCYC-1102 study and its extended study PCYC-1103 (NCT01109069) was included in patients receiving iluteni monotherapy as a first-line treatment or recurrent/incurable CLL/SLL.
expected seven-year progression-free survival (PFS) rate for patients treated with iruthini as a first-line treatment was 83%, compared with 34% for patients with recurrent/incurable diseases.
-
Blood: Hematopogenic cell high expression CXCL4 promotes progression of MMPN bone marrow fibrosis.
Time of Update: 2020-08-22
the study shows that in MPN, high expression of CXCL4 has a fibrosis-promoting effect and is a regulatory factor for characteristic inflammation.
-
Blood: Effects of TP53 mutations on MDS and secondary AML prognosation.
Time of Update: 2020-08-22
Sotic cell gene mutations are a key determinant of prognosis in patients with bone marrow proplation abnormal syndrome (MDS) and secondary acute myeloid leukemia (SAML).
-
Novarte CAR-T therapy Kymriah: Reached the end of the follicle lymphoma trial.
Time of Update: 2020-08-22
Novarte's CAR-T cell therapy Kymriah (tisagenlecleucel) treats recurrent or incurable follicular lymphoma, and an interim analysis of the ELARA Phase 2 trial shows that Kymriah has reached the primary endpoint of total remission rate (CRR).
-
Blood: Clinical characteristics and prognosis of out-of-knot DLBCL during the Lycoxi monoa resistance era.
Time of Update: 2020-08-22
in multivariable analysis, the OS and progression-free survival rates were worse in patients with non-lymph nodes (3.44 and 3.25, respectively).
, the prognosis of patients with DLBCL outside phase I was worse than that of patients with end-of-life.
-
Is the re-birth of blood heavyweight CAR-NK more effective than CAR-T cell immunotherapy?
Time of Update: 2020-08-22
Figure 1: On July 2, 2020, a new study published online in the Journal of Blood, "CAR-modified memory-like NK cells potent responses to NK-resistant lymphomas," a team of researchers from the University of Washington School of Medicine combined two strategies of immunotherapy, CAR (embedded antigen receptors) and MNK cells, into a new therapy, CAR-ML NK cell therapy.
-
Inventory: A selection of Blood studies from August 6, 2020.
Time of Update: 2020-08-22
Inhibition of THEJAK/STAT path to enhance the apoptosis sensitivity of CD8 T cells to desermison-induced https://doi.org/10.1182/blood.2020006075 cytokine storm syndrome (CSS) is a severe hyper-inflammatory state characterized by excessive immune system activation, resulting in organ damage and patient death.
-
Blood:ETV6 mediated molecular basis for acute lymphocytic leukemia susceptible in children.
Time of Update: 2020-08-21
, Nishii and other researchers have found recurrent ETV6 embryoline variants associated with THE risk, which together represent a new type of leukemia susceptible syndrome.
two ETV6 embryoline variants can cause both AML and ALL, along with genetic damage specific to the leukemia genome genealogy.
-
Lancet Haematol: Avadomide joint obinutuzumab treatment recurrent or refractive non-Hodgkin lymphoma.
Time of Update: 2020-08-21
this is a phase 1b dose increase and expansion study conducted at eight centres in France, Italy and the Netherlands to recruit patients with recurrent/refractive non-Hodgkin lymphoma with a diagnosed CD20 plus over the age of 18.
-
Blood: The detection of negative micro-residual lesions should be used as the end point for the treatment of high-risk multiple myeloma.
Time of Update: 2020-08-21
further isolated MRD with NGF, and then the paired MRD tumor cells were sequenced genome-wide, and found that MM patients with standard CA risk had more cloning options, high-risk MM patients had more secondary mutations, higher genomic instability, and no uniform absence or acquired genetic variation that drove MRD resistance was found.
-
The doctor even had 11 hours of surgery to kill him, heart attack.
Time of Update: 2020-08-19
when the surgeon for more than ten years had checked out high blood pressure but did not pay attention to the Guo Yingqiang, Said, Park Hua's condition is acute aortic mezzanine separation, that is, the aortic artery inner layer of the tear, the wound along the aorta all the way to the leg, the condition is very serious.
-
World's leading! China's independent research and development of acute heart attack treatment system debuted at the European Heart Conference.
Time of Update: 2020-08-19
On the afternoon of September 1, 2019, local time in Shanghai, Xu Yawei team of Shanghai Tenth People's Hospital presented the 2019 European Heart Disease Conference (ESC2019) Digital Health Stage with an informatization solution for acute myocardial infarction.
